SCI时时刷

search
+
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes across several solid tumour types. Prominent efforts h...
Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL
Haematopoietic stem cell transplantation (HSCT) and CD19-targeted chimeric antigen receptor (CAR) T cells are potentially ...
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids through apoptosis, necrosis or activ...
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Immune-checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced-stage squamous non-small-cell lun...
Women with clinically node negative breast cancer can safely avoid axillary surgery
Axillary nodal status provides important information on the prognosis of women with invasive breast cancer. However, the r...
Treatment advances across the cervical cancer spectrum
Treatment advances across the cervical cancer spectrum
Cervical cancer is preventable with screening and vaccination approaches; however, access to these preventative measures i...
Imlunestrant shows efficacy both with and without abemaciclib
Various endocrine therapies and CDK4/6 inhibitors have improved the treatment of ER+HER2−breast cancer, although resistanc...
cfDNA screening for fetal aneuploidy facilitates maternal cancer detection
Sequencing of plasma cell-free DNA (cfDNA) is commonly performed during pregnancy to screen for fetal aneuploidy. Now, dat...
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death ...
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease
The combination of the anti-PD-1 antibody nivolumab plus the anti-CTLA4 antibody ipilimumab showed promising efficacy outc...
Leptomeningeal metastatic disease: new frontiers and future directions
Leptomeningeal metastatic disease: new frontiers and future directions
Leptomeningeal metastatic disease (LMD), encompassing entities of ‘meningeal carcinomatosis’, neoplastic menin...
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
Immune-checkpoint inhibitors (ICIs) are being tested as neoadjuvant therapies in various solid tumours, including in patie...
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer
As one of the first studies testing perioperative anti-PD-(L)1 antibodies in resectable non-small-cell lung cancer (NSCLC)...
Synthetic lethal strategies for the development of cancer therapeutics
Synthetic lethal strategies for the development of cancer therapeutics
Synthetic lethality is a genetic phenomenon whereby the simultaneous presence of two different genetic alterations impairs...
Getting the right combination to break the epigenetic code
Getting the right combination to break the epigenetic code
Rapid advances in the field of epigenetics have facilitated the development of novel therapeutics targeting epigenetic mec...
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL
Chimeric antigen receptor (CAR) T cells have emerged as an effective treatment option for patients with relapsed and/or re...
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
Metastasis is the leading cause of cancer-related death in patients with solid tumours. Current imaging technologies are n...
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
The discovery of the association between EGFR mutations and the efficacy of EGFR tyrosine-kinase inhibitors (TKIs) has rev...
HIPEC is effective in patients undergoing cytoreduction for recurrent ovarian cancer
Women with late recurrence of advanced-stage ovarian cancer typically receive preoperative chemotherapy followed by cytore...
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC
Many patients with advanced-stage gastric or gastro-oesophageal junction cancer (G/GEJC), particularly those deemed inelig...
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm
Over the past few years, several novel systemic treatments have emerged for patients with treatment-refractory metastatic ...
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Chimeric antigen receptor (CAR) T cells are revolutionizing cancer therapy, particularly for haematological malignancies, ...
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes
Approximately 40% of hormone receptor-positive (HR+), HER2-negative (HER2–) breast cancers harbour activating mutations in...
Expanding the use of T-DXd in metastatic HR-positive breast cancer: where are we now?
The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic horm...
On the cusp of targeted therapy for cancer cachexia — what clinical benefits might we promise our patients?
A number of therapeutics that target mediators of signalling in the hypothalamic and brainstem regions that control appeti...
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia
The B cell receptor (BCR) signalling pathway has an integral role in the pathogenesis of many B cell malignancies, includi...
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress
Author notesThese authors contributed equally: Shelley A. Jazowski, Rahul K. Nayak.Authors and AffiliationsDepartment of H...
Cadonilimab is effective and safe in recurrent cervical cancer
The standard-of-care (SOC) first-line treatment for patients with recurrent or metastatic cervical cancer is chemotherapy ...
NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3
Competing interests Z.A.W. is a NAPOLI 3 study investigator; has received grants...
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’
Competing interests C.N.-P. receives institutional research funding from Theriva...
阅读更多
format_indent_increase